"Accelerate your drug discovery" is killing your pipeline
Strategic Marketing
Jul 8, 2026
Open the homepages of ten life science companies and you will read the same sentences: “Accelerate your drug discovery”. “End-to-end platform”. “AI-powered”.
The phrases feel safe because everyone reaches for them. That is exactly the problem.
Generic biotech marketing messaging does not simply fail to help you. It costs you pipeline and capital, because the buyers and investors you are trying to reach now route their attention, and their money, toward the companies that say something specific.
But here is the part most teams miss. Generic messaging is rarely a writing problem. It is a positioning problem.
Messaging is the symptom. Positioning is the cause.
Two different jobs get collapsed into one, and it shows.
Positioning is an internal exercise. It is the decision about what category you are in, what you are genuinely best at, and who you are for. Messaging is the external translation of that decision into words, story, and a homepage. Messaging is downstream of positioning. You cannot write your way out of a positioning you have not done.
When a company lands on “accelerate your drug discovery,” it usually has not made those internal calls. There is no sharp answer to “what are we, specifically, and for whom,” so the copy defaults to the safest, broadest phrase available. The cliché is the tell.
The “everything to everyone” trap
The most common positioning mistake is trying to be for everyone. It feels safe, and it is the fastest route to generic messaging.
Picture coffee served lukewarm to please both the people who want it hot and the people who want it iced. It offends no one and delights no one. Positioning that tries to fit every buyer produces messaging that moves none of them.
Good positioning does the opposite. It lets the right customer read your homepage and think “this is for me,” and it lets the wrong-fit customer self-select out. That self-selection is a feature, not a cost. The goal of a position is not to be acceptable to everyone; it is to be the obvious choice for someone. A claim everyone could make is a claim that helps no one decide.
The category is loud. A clear position is how you get heard.
The noise is not your imagination. The market for AI in drug discovery alone is projected to grow from $3.25 billion in 2026 to $10.29 billion by 2031, and the field is crowded with well-funded companies, from Exscientia and Insilico to BenevolentAI, Atomwise, and Recursion, all describing themselves in strikingly similar terms.
Meanwhile, by Sifted’s account, the industry is “still waiting for proof” that the broad promise has paid off. When claims outrun evidence across an entire category, every extra “AI-powered, end-to-end” line reads as more noise.
The instinct in a loud room is to talk louder. The companies that get heard do the opposite. They get specific, because they have decided what they are. McKinsey’s read on AI in biopharma is that the winners focus on “specific scientific and operational pain points” rather than sweeping claims. The market agrees: in 2025, biopharma capital concentrated on “asset-centric companies and differentiated platforms that address well-defined biological or technical bottlenecks” (BioSpace, Feb 2026). Money follows a clear position. The generic middle gets starved.
Why sameness costs you real pipeline
For a reagents and tools company, the buyer is usually a scientist. Adjectives do not move them. They are trying to picture whether your product belongs in their workflow, and a generic claim gives them nothing to picture.
Imagine a scientist scanning a shortlist of eight vendors before a conference. Seven of them lead with “accelerate your drug discovery.” The eighth says it cuts failed-batch rates in antibody screening. Only one gave the scientist a reason to stop and read.
The cost of blending in is the quiet kind of failure: longer sales cycles, partnerships that never quite materialize, a pipeline that stalls without anyone telling you why. Customers and investors understand what the technology does, but they cannot picture needing it. That is not a science problem. It is a positioning problem, and it is fixable. Therapeutics teams hit the same trap in front of investors, who hear ten oncology pitches a week in near-identical language. We dig into that in why “the science speaks for itself” is the most expensive myth in biotech.
What a clear position sounds like
One company we worked with used to describe itself like this:
“We create libraries and sell them.”
After the positioning work, the same company described the same science like this:
“We map the genetic landscape before your clinical trial to reduce waste and de-risk the path to the clinic.”
Nothing about the technology changed. What changed is that the second sentence has decided what the company is and who it is for, so it answers the question a customer was about to ask instead of making them ask it. That is the shift behind the Atlas Biotech work.
Do the positioning, then write the message
Specificity and scientific accuracy are not in tension. You do not have to dumb anything down. You have to decide, then translate.
1. Choose the category and the workflow you change, not the technology you built. Your customer cares about their process, not your architecture.
2. Decide who it is for, and who it is not. If your position has no one it is not for, it is not a position.
3. Name the outcome in their language. “Higher hit rates,” “fewer failed batches,” and “data your reviewers will trust” are results, not capabilities.
4. Pressure-test it. Cut any phrase a competitor could lift verbatim, and check that a smart non-specialist can repeat back what you do.
For founders heading into a raise, this is the same discipline behind what pre-seed investors actually need to see: one clear problem statement, not a feature list.
Positioning is a strategy problem, not a copywriting one
Generic messaging rarely means the science is weak. It usually means the positioning was never settled, so no one could translate it. That is exactly where generalist agencies fall short: they polish the message without ever doing the internal work underneath it.
Saying something specific takes two capabilities at once. You need the scientific fluency to understand what is genuinely differentiated about your work, and the strategic judgment to choose a position and frame it for the people who decide your funding and your revenue. That combination is the whole job. It is also how we approach positioning: settle the position first, then build the story around what is true and what is yours.
If you are not sure whether your messaging sounds like everyone else’s, that is worth knowing before your next raise or launch. Apply for Signal for an honest, external read on how your story is landing.